NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
週一，愛文思控股有限公司（NASDAQ:NVCR）和再鼎醫藥有限公司（NASDAQ:ZLAB）公佈了第3期PANOVA-3試驗的前線數據，該試驗評估了將腫瘤治療電場（TTFields）療法與吉西他濱和納帕紫杉醇同時作爲不可切除的局部晚期胰腺腺癌的一線治療。
The pivotal trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control.
該關鍵試驗達到了主要終點，證明了與對照組相比中位總生存期（mOS）具有統計學上顯著的改善。
Also Read: FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
另請參閱：FDA批准NovoCure生產便攜式設備，爲以往接受治療的肺癌患者產生腫瘤治療電場
In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; P=0.039) (N=571).
在意圖治療人群中，接受TTFields療法與吉西他濱和納帕紫杉醇同時治療的患者的mOS爲16.20個月，而單獨接受吉西他濱和納帕紫杉醇治療的患者爲14.16個月，這是一項統計學上顯著的2.0個月的改善（風險比=0.819; P=0.039）（N=571）。
The survival rate benefit for patients treated with TTFields therapy increased over time, with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months.
接受TTFields療法治療的患者的生存率益處隨時間增加，在12個月時總體生存率提高了13%，在24個月時生存率提高了33%。
TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets. Zai Lab plans to file for regulatory approval in China.
TTFields療法耐受性良好，安全性與先前的臨床研究一致。愛文思控股計劃在美國、歐盟、日本和其他關鍵市場申請監管批准。再鼎醫藥計劃在中國申請監管批准。
Novocure continues to follow patients in its Phase 2 PANOVA-4 trial, which is exploring the use of TTFields therapy together with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment, and data are anticipated in 2026.
愛文思控股繼續追蹤其第2期PANOVA-4試驗中的患者，該試驗探索了將TTFields療法與阿特珠單抗、吉西他濱和納帕紫杉醇結合治療轉移性胰腺癌。 PANOVA-4已完成招募，並預計將於2026年公佈數據。
Price Action: NVCR stock is up 31% at $26.26 at last check Monday.
價格走勢：NVCR股票在上週一最後一次檢查時漲幅爲31%，報26.26美元。
- Amazon And Walmart Dominate Black Friday As Online Sales Soar 14.6%
- 亞馬遜和沃爾瑪主導黑色星期五，隨着在線銷售飆升14.6%
Photo via Shutterstock.
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
